Showing results (181-190 of 288) with videos related to
Sort By:
Pageof 29
Plos One|July 10, 2023
Validation of a French version of the Breakthrough Pain Assessment Tool in cancer patients: Factorial structure, reliability and responsivenessElise Perceau-Chambard, Sylvain Roche, Colombe Tricou, et al.European Journal of Pain (London, England)|January 22, 2011
Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategiesAndrew Davies, Giovambattista Zeppetella, Steen Andersen, et al.Blood|July 12, 2013
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)John Radford, Andrew Davies, Guillaume Cartron, et al.Journal of Critical Care|August 30, 2008
Early decompressive craniectomy for patients with severe traumatic brain injury and refractory intracranial hypertension--a pilot randomized trialD James Cooper, Jeffrey V Rosenfeld, Lynnette Murray, et al.Diabetologia|August 11, 2020
Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programmeYiqiao Xin, Andrew Davies, Andrew Briggs, et al.European Journal of Ophthalmology|October 19, 2020
Changing clinical patterns of Rhegmatogeneous Retinal Detachments during the COVID19 pandemic lockdown in the North West of the UKKirti M Jasani, Tsveta Ivanova, Francesco Sabatino, et al.The Lancet. Oncology|February 14, 2014
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 studyAndrew Davies, Francesco Merli, Biljana Mihaljevic, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2016
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin LymphomaMichinori Ogura, Kensei Tobinai, Kiyohiko Hatake, et al.Hematological Oncology|August 23, 2016
Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 studyLuca Ceriani, Sally Barrington, Alberto Biggi, et al.Journal of Drug Assessment|September 30, 2017
Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphomaRandeep Sangha, Andrew Davies, Nam H Dang, et al.Pageof 29